AASLD News

The American Association for the Study of Liver Diseases (AASLD) expresses deep concern over the 2025–2030 Dietary Guidelines for Americans (DGA), released jointly by the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Agriculture (USDA), which remove specific, evidence-based guidance on alcohol consumption. The updated guidelines advise individuals to consume less

On January 7, 2026, the Department of Health and Human Services (HHS) and the Department of Agriculture (USDA) released updated Dietary Guidelines for Americans (DGA) for 2025-2030, removing any specific guidance on alcohol consumption. The updated guidelines instead advise that people should “consume less alcohol for better overall health” and “limit beverages,” without recommending clear limits

In 2025, AASLD advanced science, strengthened education, shaped public policy, expanded global engagement, and brought the hepatology community together in powerful ways. These accomplishments reflect the collective leadership, expertise, and dedication of our members, volunteers, and professional staff. Explore the resources below to learn more about the impact achieved this year and the people

Adult Liver Transplantation: Candidate Evaluation and Adult Liver Transplantation: Diagnosis and Post-Transplant Management of Non-Graft-Related Complications ALEXANDRIA, VA — The American Association for the Study of Liver Diseases (AASLD) and American Society of Transplantation (AST) are pleased to announce two new Practice Guidelines published in HEPATOLOGY and Liver Transplantation, AASLD’s

ALEXANDRIA, Virginia — The American Association for the Study of Liver Diseases (AASLD) is pleased to announce the appointment of Naga Chalasani, MD, FAASLD, of Indiana University School of Medicine, and Laura E. Nagy, PhD, FAASLD, of Cleveland Clinic, as the next Co-Editors-in-Chief of HEPATOLOGY. HEPATOLOGY, the premier publication in the field of liver disease, publishes original, peer-reviewed

The American Association for the Study of Liver Diseases (AASLD) and its undersigned partner organizations, American College of Gastroenterology (ACG), the American Gastroenterological Association (AGA), American Society for Gastrointestinal Endoscopy (ASGE), Infectious Diseases Society of America (IDSA), and North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN)

New guidance provides clinicians with practical, evidence-based criteria for patient selection, comorbidity management, and monitoring the safety and effectiveness of semaglutide therapy for metabolic dysfunction-associated steatohepatitis (MASH). The American Association for the Study of Liver Diseases (AASLD) announces the updated Practice Guidance on Semaglutide therapy for Metabolic

The American Association for the Study of Liver Diseases (AASLD) acknowledges the recent market withdrawal of obeticholic acid (OCA) for the treatment of primary biliary cholangitis (PBC) by Intercept Pharmaceuticals. OCA has served as a second-line therapeutic option for patients with an inadequate response to ursodeoxycholic acid, and its withdrawal marks a significant change in the PBC

The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) are pleased to announce a new Practice Guideline on Treatment of Chronic Hepatitis B published in HEPATOLOGY, the premier publication in the field of liver disease. Chronic hepatitis B (CHB) is a dynamic disease that progresses through multiple phases. The new guideline provides

AASLD proudly recognizes the Department of Veterans Affairs (VA) Hepatitis Innovation Team (HIT) and the HIT collaborating offices with VA ALEXANDRIA, Virginia — Each year, the American Association for the Study of Liver Diseases (AASLD) presents its most prestigious awards to recognize exceptional leadership, mentorship, service, and advocacy across the liver community. AASLD proudly announces

ALEXANDRIA, Virginia — The American Association for the Study of Liver Diseases (AASLD) is pleased to share the Special Issue on Cholestasis published by HEPATOLOGY, the premier publication in the field of liver disease. Cholestatic liver diseases—such as primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), and IgG4-related cholangitis—pose a significant but often

Alexandria, Virginia — The American Association for the Study of Liver Diseases (AASLD) proudly announces the 2025 Distinguished Award recipients, honoring individuals whose outstanding contributions have shaped the field of hepatology and advanced the care of patients with liver disease. Each year, AASLD presents its most prestigious awards to recognize exceptional leadership, mentorship, service

ALEXANDRIA, Virginia — The American Association for the Study of Liver Diseases (AASLD) and the American Society of Transplantation (AST) are pleased to announce the latest Practice Guideline on Adult Liver Transplantation: Diagnosis and Management of Graft-Related Complications published in Liver Transplantation, the premier journal equipping clinicians and researchers with the latest insights in

The American Association for the Study of Liver Diseases (AASLD) applauds the U.S. Food and Drug Administration’s (FDA) recent approval of Wegovy®, widely recognized for weight loss and diabetes management, as a new treatment for adults with Metabolic dysfunction-Associated Steatohepatitis (MASH) and moderate to advanced liver fibrosis. MASH, a subset of Metabolic dysfunction-Associated Steatotic